Author: Dino Mustafić

February 16, 2021 Off

Novavax’ vaccine in South Korea

By Dino Mustafić

Novavax and SK Bioscience, a vaccine business subsidiary of SK Group, today announced an expanded collaboration and license agreement to include for Bioscience a license to make and sell Novavax’ Covid-19 vaccine to the Korean government.

February 15, 2021 Off

Basilea divests its Chinese R&D subsidiary to PHT International

By Dino Mustafić

Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today that it has entered into an agreement to divest its Chinese research and development (R&D) subsidiary Basilea Pharmaceutica China Ltd. (“BPC”), by selling BPC’s parent company BPh Investitionen Ltd. to the U.S.-based custom manufacturing organization PHT International Inc. (“PHT”).

February 11, 2021 Off

Recipharm bolsters biologics offering

By Dino Mustafić

Global contract development and manufacturing organisation (CDMO), Recipharm, has successfully extended its manufacturing license to include immunology products, allowing them to cater for customers’ vaccine products at clinical and commercial scales, in both freeze-dried and liquid forms.

February 3, 2021 Off

BMS sells its Swiss-based factory to WuXi STA

By Dino Mustafić

WuXi STA has agreed to purchase Bristol Myers Squibb’s manufacturing facility in Couvet, Switzerland. The Couvet site will be the first facility in Europe for WuXi STA, a leading Contract Development and Manufacturing Organization. The acquisition will enhance WuXi STA’s existing capabilities while growing capacity to support its partners’ life-saving work.